PLUS THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.2M | $5.8M | $4.9M | — | — |
| Research and development | $8.4M | $10.6M | $9.7M | $9.7M | $5.3M |
| Operating expenses | $20.5M | $20.5M | $18.2M | $19.9M | $12.5M |
| Operating income | -$15.3M | -$14.7M | -$13.3M | -$19.7M | -$12.5M |
| Interest expense | $548,000 | $179,000 | $395,000 | $711,000 | $932,000 |
| Pretax income | -$22.4M | -$13.0M | — | — | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$22.4M | -$13.0M | -$13.3M | -$20.3M | -$13.4M |
| Balance Sheet | |||||
| Cash and equivalents | $4.3M | $76,000 | $8.6M | $18.1M | $18.4M |
| Current assets | $15.2M | $5.3M | $9.8M | $21.8M | $19.7M |
| Total assets | $16.3M | $6.6M | $11.4M | $23.9M | $22.0M |
| Current liabilities | $12.3M | $15.6M | $10.7M | $11.9M | $5.9M |
| Total liabilities | $12.3M | $15.6M | $12.7M | $17.4M | $11.1M |
| Stockholders' equity | $4.0M | -$8.9M | -$1.3M | $6.4M | $10.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$20.8M | -$10.6M | -$12.9M | -$13.0M | -$10.3M |
| Depreciation and amortization | $445,000 | $872,000 | $628,000 | $619,000 | $395,000 |
| Stock-based compensation | $1.5M | $550,000 | $569,000 | $606,000 | $606,000 |
| Capital expenditure | $67,000 | $146,000 | $160,000 | — | — |
| Free cash flow | -$20.8M | -$10.7M | -$13.0M | — | — |
| Share repurchases | — | $374,000 | $126,000 | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 6.9M · Free float 23.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.